Importantly, it should be noted that IL-6 inhibitors show significant efficacy in diseases, such as cytokine release syndrome where IL-6 levels are nearly 100-fold greater than those in patients with COVID-19 (32). This evidence concerns the gene IL6 and COVID-19.